Nanjing Bioheng Biotech Co., Ltd.
Nanjing Bioheng Biotech Co., Ltd.
Explore linked clinical trials.10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, acquired idiopathic inflammatory myopathy, anti-glomerular basement membrane disease, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, glomerulonephritis, immune system disorder, interstitial lung disease, kidney disorder, lobular neoplasia, lung disorder, necrotizing vasculitis, nephritis, respiratory system disorder, skin disorder, skin vascular disease, systemic lupus erythematosus, systemic sclerosis, urinary system disorder, vascular disorder, vasculitis | Recruiting | Early phase 1 | 2026-08-03 | NCT07203404 | |
| CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, acquired idiopathic inflammatory myopathy, anti-neutrophil cytoplasmic antibody-associated vasculitis, arthritic joint disease, arthropathy, autoimmune disease, cardiovascular disorder, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, necrotizing vasculitis, nervous system disorder, neuromuscular disease, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, skin disorder, skin vascular disease, systemic lupus erythematosus, systemic sclerosis, vascular disorder, vasculitis | Not yet recruiting | Early phase 1 | 2026-07-16 | NCT07596680 | |
| CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, multiple sclerosis, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy | Recruiting | Early phase 1 | 2026-05-12 | NCT07337785 | |
| Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, acquired idiopathic inflammatory myopathy, anti-neutrophil cytoplasmic antibody-associated vasculitis, arthritic joint disease, arthropathy, autoimmune disease, cardiovascular disorder, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, necrotizing vasculitis, nervous system disorder, neuromuscular disease, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, skin disorder, skin vascular disease, systemic lupus erythematosus, systemic sclerosis, vascular disorder, vasculitis | Recruiting | Early phase 1 | 2026-03-06 | NCT06548607 | |
| UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases | Evans syndrome, Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Recruiting | Early phase 1 | 2026-03-02 | NCT07441525 | |
| Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases | Skin and Connective Tissue Diseases, acquired idiopathic inflammatory myopathy, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, connective tissue disorder, immune system disorder, necrotizing vasculitis, skin disorder, skin vascular disease, systemic lupus erythematosus, systemic sclerosis, vascular disorder, vasculitis | Recruiting | Early phase 1 | 2026-02-02 | NCT06775912 | |
| A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Active, not recruiting | Early phase 1 | 2025-08-26 | NCT07142161 | |
| CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia | Bone Marrow Failure Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Relapse, anemia, aplastic anemia, bone marrow disorder, hematologic disorder | Recruiting | Phase 1 | 2025-07-24 | NCT06622694 | |
| RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies | Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, lymphoma, neoplasm | Recruiting | Phase 1 | 2024-12-13 | NCT06732492 | |
| A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Early phase 1 | 2020-12-28 | NCT04227015 |